REGENXBIO Inc. (RGNX) held by 14 SEC 13F Filers

REGENXBIO Inc. (NASDAQ:RGNX) recovered 92.6% of its value since hitting low of $23.25. The recent move of -2.76% drop pushed the stock to close at $44.78 when trading ended on 01/11/2019. At recent session, the prices were hovering between $44.7 and $47.2989. This company shares are 72.11% off its target price of $77.07 and the current market capitalization stands at $1.65B. The recent change has given its price a -18.9% deficit over SMA 50 and -47.38% deficit over its 52-week high. The stock witnessed -16.19% declines, -25.69% declines and -40.09% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RGNX’s volatility during a week at 6.01% and during a month it has been found around 8.12%.

REGENXBIO Inc. (RGNX) Top Holders

Institutional investors currently hold around $1.28 billion or 81.7% in RGNX stock. Look at its top three institutional owners. Blackrock Inc. owns $211.68 million in REGENXBIO Inc., which represents roughly 12.83% of the company’s market cap and approximately 16.59% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 2,805,969 shares of the stock are valued at $125.65 million. The third largest holder is State Street Corp, which currently holds $75.91 million worth of this stock and that ownership represents nearly 4.6% of its market capitalization.

REGENXBIO Inc. 13F Filings

At the end of September reporting period, 137 institutional holders increased their position in REGENXBIO Inc. (NASDAQ:RGNX) by some 5,466,265 shares, 72 decreased positions by 2,932,583 and 14 held positions by 20,096,941. That puts total institutional holdings at 28,495,789 shares, according to SEC filings. The stock grabbed 48 new institutional investments totaling 839,401 shares while 22 institutional investors sold out their entire positions totaling 589,342 shares.


Multiple company employees have indulged in significant insider trading. REGENXBIO Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP, General Counsel Christmas Patrick J. has sold 5,000 shares of REGENXBIO Inc. (RGNX) in trading session dated Dec. 18, 2018. These shares are worth $237,700 and were traded at $47.54 each. The SEC filing shows that Mills Kenneth T. performed a sale of 15,000 shares. The President and CEO disposed these shares by way of transaction on Dec. 17, 2018. The company’s shares were given away at $46.73 per share worth to an income of some $700,950 on account of Mills Kenneth T..

CFO, Vasista Vittal, sold 7,500 common shares of REGENXBIO Inc. (RGNX) in the open market. In a transaction dated Dec. 17, 2018, the shares were put up for sale at an average price of $46.35, raking in a sum of $347,625. After this sale, 122,283 common shares of RGNX are directly owned by the insider, with total stake valued at $5,475,833.

In the transaction dated Dec. 03, 2018, the great number of shares disposed came courtesy the President and CEO; Mills Kenneth T. disposed a total of 20,000 shares at an average price of $60.4, amounting to approximately $1,208,000. The insider now directly owns 231,000 shares worth $10,344,180.

REGENXBIO Inc. (RGNX) Analyst Guide

Several analysts have released their opinion on REGENXBIO Inc. (NASDAQ:RGNX), with 0 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.